Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States
The developer is a United Kingdom-based drug development and manufacturing company, providing integrated R&D and manufacturing capabilities to accelerate entry of PIP-101 in the U.S. market.
Shorla Oncology to receive the exclusive rights to commercialize PIP-101 in the U.S.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Shorla Oncology (‘Shorla’), a U.S.-Ireland pharmaceutical company, today announced it has entered into a licensing agreement and strategic partnership with a U.K.-based innovative drug development and manufacturing company. Under the terms of the agreement, Shorla will obtain an exclusive license from the developer to register and commercialize PIP-101, the first palatable oral solution of the related chemotherapeutic agent in the